BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 15542813)

  • 1. DNA methylation and cancer.
    Das PM; Singal R
    J Clin Oncol; 2004 Nov; 22(22):4632-42. PubMed ID: 15542813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results.
    Digel W; Lübbert M
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):1-11. PubMed ID: 15886007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
    Murgo AJ
    Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenome: a new target in cancer therapy.
    Giacinti L; Vici P; Lopez M
    Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic alterations and cancer: new targets for therapy.
    Allen A
    IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Epigenome and cancer: new possibilities of cancer prevention and therapy?].
    Paluszczak J; Baer-Dubowska W
    Postepy Biochem; 2005; 51(3):244-50. PubMed ID: 16381168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
    Barton CA; Hacker NF; Clark SJ; O'Brien PM
    Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic changes in solid and hematopoietic tumors.
    Toyota M; Issa JP
    Semin Oncol; 2005 Oct; 32(5):521-30. PubMed ID: 16210093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Contribution of molecular biology to new diagnostic and/or prognostic markers characterization in cancerogenesis].
    de Fraipont F
    Ann Biol Clin (Paris); 2007; 65(1):21-6. PubMed ID: 17264035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
    Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
    Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic changes in cancer.
    Grønbaek K; Hother C; Jones PA
    APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of the MGMT gene in cancer.
    Soejima H; Zhao W; Mukai T
    Biochem Cell Biol; 2005 Aug; 83(4):429-37. PubMed ID: 16094446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
    Xi S; Dyer KF; Kimak M; Zhang Q; Gooding WE; Chaillet JR; Chai RL; Ferrell RE; Zamboni B; Hunt J; Grandis JR
    J Natl Cancer Inst; 2006 Feb; 98(3):181-9. PubMed ID: 16449678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets.
    Herranz M; Esteller M
    Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.